Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan

DARU, Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2013, Pages

  Ebara, Takeshi ^a   Ohno, Tatsuya ^b   Nakano, Takashi ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Cost effectiveness analysis; Japan; Molecular targeting drugs; Simple quantitative calculation

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; EVEROLIMUS; LAPATINIB; PACLITAXEL; PANITUMUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

BREAST CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; JAPAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84878859643     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-21-40     Document Type: Review

References (25)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan (in Japanese) http://www.ganjoho.jp/professional/statistics/ statistics.html#01
2. Medical cost statistics in Japan (in Japanese) http://www.e-stat.go.jp/ SG1/estat/List.do?lid=000001101011
3. Medical drug information (in Japanese) http://www.info.pmda.go.jp/ psearch/html/menu-tenpu-base.html
4. Ministry of Health, Labour and Welfare database (in Japanese) http://www.mhlw.go.jp/toukei/youran/indexyk-2-1.html
5. Drug search ePHAMA (in Japanese) http://www.e-pharma.jp/index.html
6. Paclitaxel-carboplatin alone or with Bevacizumab for non-small-cell lung cancer. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH, N Engl J Med 2006 355 24 2542 2550 10.1056/NEJMoa061884 17167137 (Pubitemid 44917502)
7. RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Lancet 2008 372 9637 449 456 10.1016/S0140-6736(08)61039-9 18653228
8. TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, N Engl J Med 2007 356 2 125 134 10.1056/NEJMoa060655 17215530 (Pubitemid 46089673)
9. SHARP Investigators Study Group.: Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, N Engl J Med 2008 359 4 378 390 10.1056/NEJMoa0708857 18650514
10. Sunitinib versus interferon Alfa in metastatic renal-cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA, N Engl J Med 2007 356 2 115 124 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
11. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R, Oncologist 2010 15 4 428 435 10.1634/theoncologist. 2009-0178 20332142
12. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D, N Engl J Med 2006 355 26 2733 2743 10.1056/NEJMoa064320 17192538 (Pubitemid 46021510)
13. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG, J Clin Oncol 2007 25 13 1658 1664 10.1200/JCO.2006.08.1620 17470858 (Pubitemid 46797944)
14. American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, Ubel PA, Schnipper LE, J Clin Oncol 2009 27 23 3868 3874 10.1200/JCO.2009.23. 1183 19581533
15. Cost-effectiveness analysis in oncology. Earle CC, Coyle D, Evans WK, Ann Oncol 1998 9 5 475 482 10.1023/A:1008292128615 9653486 (Pubitemid 28270633)
16. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K, Health Econ 2010 19 422 437 10.1002/hec.1481 19382128
17. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. Fojo T, Grady C, J Natl Cancer Inst 2009 101 15 1044 1048 10.1093/jnci/djp177 19564563
18. Economic evaluation of stereotactic radiotherapy. (in Japanese). Takura T, J Clin Exp Med 2008 226 3 247 252
19. Cost-effectiveness of carbon ion radiation therapy for locally recurrent rectal cancer. Mobaraki A, Ohno T, Yamada S, Sakurai H, Nakano T, Cancer Sci 2010 101 8 1834 1839 10.1111/j.1349-7006.2010.01604.x 20500516
20. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl, N Engl J Med 2003 348 11 994 1004 10.1056/NEJMoa022457 12637609 (Pubitemid 36302244)
21. American Society of Clinical Oncology Provisional Clinical Opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL, J Clin Oncol 2009 27 12 2091 2096 10.1200/JCO.2009.21.9170 19188670
22. Cancer care, money, and the value of life: whose justice? Which rationality? Sulmasy DP, J Clin Oncol 2007 25 2 217 222 10.1200/JCO.2006.08.0481 17210943 (Pubitemid 350003037)
23. Pharmacoeconomic analysis of consolidation therapy with Pemetrexed after first-line chemotherapy for non-small cell lung cancer. Tsuchiya T, Fukuda T, Furuiye M, Kawabuchi K, Lung Cancer 2011 74 3 521 528 10.1016/j.lungcan.2011.04. 002 21570734
24. Cost-utility analysis: Use QALYs only with great caution. McGregor M, Can Med Assoc J 2003 168 4 433 434 (Pubitemid 36255729)
25. Health economics: Life in the balance. Cressey D, Nature 2009 461 7262 336 339 10.1038/461336a 19759594